Amy KruseinPrime Movers LabWhy We Invested in Gilgamesh (Again)Substantial progress on new programs and a clear path to the clinic for two lead compounds4 min read·Dec 15, 2022----
Amy KruseinPrime Movers LabThe Neurotech Revolution Goes to Washington!Insights from Paradromics CEO Matt Angle on the Bioeconomy and Biomanufacturing White House Summit7 min read·Sep 20, 2022----
Amy KruseinPrime Movers LabWomen Make Great Scientists, Engineers, Investors, CEOs and more!A few memories and some thoughts from my recent meetings and travels11 min read·Jun 27, 2022----
Amy KruseinPrime Movers LabWebinar Recap: Regenerative MedicineUnlocking the innate intelligence of the body to rebuild and repair5 min read·Feb 23, 2022----
Amy KruseinPrime Movers LabPrime Movers Lab Webinar Series: Regenerative MedicineExploring leading research and development in tissue repair and organ regeneration4 min read·Feb 9, 2022----
Amy KruseinPrime Movers LabWhat to Watch — Life Sciences 2022What surprises might this year hold?9 min read·Jan 18, 2022--1--1
Amy KruseinPrime Movers LabWhy We Invested in IridiaHarnessing nature’s perfect data storage system3 min read·Dec 14, 2021----
Amy KruseinPrime Movers LabWhy We Invested in CognixionUnlocking the cognitive capacity of millions of individuals3 min read·Nov 16, 2021----
Amy KruseinPrime Movers LabWebinar Recap: The Emerging Promise of NeuromodulationInsights from a stimulating discussion with experts in the field4 min read·Nov 5, 2021----
Amy KruseinPrime Movers LabPrime Movers Lab Webinar Series: The Emerging Promise of NeuromodulationTherapies for the Body and Brain without Drugs3 min read·Oct 27, 2021--1--1